AGEN — AGENUS INC

—
Nasdaq · Health Care · Biotechnology · CIK 1098972 ·
Last close
$6.21
Market Cap
$280.98M
52W High
$10.31
52W Low
$2.71
ADV30
757,488
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 31,488,000 19,842,000 11,408,000 2,734,000 245,546,000 66,936,000 357,698,000
Jun 2026 34,518,000 19,759,000 11,293,000 -550,000 172,692,000 18,738,000 378,542,000
Mar 2026 33,736,000 21,914,000 15,054,000 39,226,000 186,456,000 34,996,000 414,439,000
Dec 2025 34,204,000 26,693,000 14,398,000 -10,578,000 226,798,000 2,998,000 504,659,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-98,504,000
Investing CF
$70,075,000
Financing CF
$35,748,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
$-54,000
EPS Diluted TTM
$1.95
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,144,089,000
Inventory
—
Receivables
$22,341,000
ST Investments
—
EBIT TTM
$151,038,000
Pretax Income TTM
$91,938,000
Interest Exp TTM
$59,100,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$133,946,000
EBITDA
$54,362,000
Free Cash Flow
$-8,132,000
Enterprise Value
$269,256,544
Total Cash
$86,936,000
Total Debt
$39,464,000
Shares Out
45,246,510
Trailing EPS
$0.23
Book Value
$-2.33
ROE
—
ROA
13.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 114,196,000 -20,556,000 115,000 226,798,000 504,659,000 -271,111,000 -77,195,000
Dec 2024 103,463,000 -124,429,000 -227,212,000 226,271,000 532,695,000 -326,380,000 -158,315,000
Dec 2023 156,314,000 -160,105,000 -245,761,000 313,913,000 462,295,000 -160,331,000 -224,202,000
Dec 2022 98,024,000 -180,242,000 -220,074,000 413,556,000 468,458,000 -61,278,000 -175,373,000

TTM Snapshot

Revenues TTM
$132,693,000
NetIncome TTM
$91,796,000
OpCashFlow TTM
—
Assets (Latest)
$172,692,000
Forward EPS
$-0.16

Max Pain — expiry 2027-01-15

max pain strike: $5.00 · spot: $6.40 · call oi: 4,845 · put oi: 1,223
Expected Move to 2027-01-15: ±$1.85 (28.91%) — implied range $4.55 – $8.25 · ATM straddle on $6.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EDIT Editas Medicine, Inc. $281.67M $1.83 —
EIKN Eikon Therapeutics, Inc. $279.06M $5.15 —
TRXB TRex Bio, Inc. $274.46M $10.00 —
AUTL Autolus Therapeutics plc $290.12M $1.09 —
AGMB AgomAb Therapeutics NV $291.55M $5.92 —

News headlines (Yahoo Finance, 1h cache)

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down
2026-11-06 15:47 · Yahoo
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
2026-11-06 14:00 · Yahoo
Agenus (AGEN) Q3 Earnings Meet Estimates
2026-11-06 00:00 · Yahoo
Agenus: Q3 Earnings Snapshot
2026-11-05 23:39 · Yahoo
Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones
2026-11-05 21:14 · Yahoo
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
2026-11-05 12:30 · Yahoo
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
2026-11-02 23:05 · Yahoo
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
2026-11-02 11:42 · Yahoo
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
2026-10-25 11:00 · Yahoo
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
2026-10-22 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.